Brand Reference: Micardis
| Metric | Verified Benchmark | Source |
|---|---|---|
| Telmisartan RxNorm Concept ID | 73494 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1420 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $76.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $7.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $9.50 / mo | 31 Zero-PHI Verified Patient Logs |
Insurmountably antagonizes vascular angiotensin II type 1 (AT1) receptors across a 24-hour trough while uniquely acting as a selective partial PPAR-gamma modulator (SPPARM), improving HOMA-IR insulin sensitivity and blunting early-morning blood pressure surges without fluid edema.
Classified under Long-Half-Life AT1 Receptor Blocker & Partial PPAR-Gamma Agonist (Rx), Telmisartan exhibits a $68.20/month gap between standard U.S. retail cash counters ($76.00) and verified direct-to-patient routing ($7.80) anchored to $0.1420 CMS unit cost.
Pharmacokinetic profiling of Telmisartan demonstrates an elimination half-life of 24 hours (longest in ARB class) with 42%–58% oral systemic bioavailability; clearance proceeds via acyl-glucuronidation only (no cyp450); >97% eliminated via biliary/fecal pathway, reaching clinical onset within 3 hours initial; full vascular remodeling at 4 weeks.
Titration schedules for Telmisartan (20 mg PO once daily → 40 mg PO once daily → 80 mg PO once daily) require excluding pregnancy; concomitant aliskiren in diabetes; bilateral renal artery stenosis; real-world patient logs highlight mild orthostatic dizziness (6% of reports), potassium +0.2 meq/l (4% of reports) alongside a 94.10% Worth-It consensus.
Across 31 verified cash-pay logs, Telmisartan achieves a 94.10% Worth-It rating with out-of-pocket spend averaging $9.50/mo versus $76.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 20 mg PO once daily for Telmisartan; monthly out-of-pocket dropped to $6.86 compared with $76.00 retail.
Completed 10 weeks on Telmisartan (40 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 80 mg PO once daily Telmisartan sourced via Cost Plus Drugs ($9.05/mo cash pay without insurance prior authorization).